Antacids of this Invention
Antacids of our invention are a totally new concept and on strength of their
exceptional qualities are likely to prove to be revolution in treatment of
acidity related gastro-intestinal disorders such as Heartburn, Dyspepsia,
Gastro-esophageal Reflux Disease (GERD), Ulcers and a number of non-specific
The inventors see
exceptional commercial opportunities in this invention and are on a look-out for
a suitable collaborator for its rapid global commercialization.
Corportations which are
already leading in antacid business are the ones which are placed very
advantageously to benefit if they take interest in this invention.
This is an equally good
opportunity for those corporations, which are not at present in antacid
business, to expand their portfolio of products. Antacids of this invention,
being a totally new concept, have no predecessors, and are a gateway to a
totally unoccupied new business space.
Distinctive features of this
opportunity are as follows:
Antacids is a treatment to
a category of life style diseases, the global market potential of which is as
attractive as that of any successful New Drug Discovery, but shall need a far
lesser lead time and expense required for hitting the market shelf from the
The presently available
antacids have disadvantages which leave a vast scope and need for better
Antacids of this invention
potentially overcome most of the disadvantages of the known antacids so far
and, in fact, are beneficial nutrients themselves with no plausible side
They are one of the most
original ideas conceived in acidity treatment so far. There is no competing
patents portfolio and practically no freedom-to-operate issues to be dealt
A part of the product is
likely to be eligible as OTC product in a very short time and rest of it may
also take a very short time as compared to other New Drug Discovered to become
eligible for OTC category.
The product of this
invention, can be described as a " Platform Product' i. e. which has a very
wide application along several lines and its fundamentals are so good that it
has come to stay for a very long time.
A note describing technical
aspect of this invention is given below as a file as a Non-Confidential
disclosure. Inventors shall be happy to provide full disclosure as soon as a
Confidentiality Agreement is signed.
Inventors have no
reservations for a thorough IPR due-diligence and freedom to operate analysis by
their prospective collaborators.
Inventors shall appreciate
expeditious handling at highest levels. They are looking forward to wrap up a
conclusive agreement by around 1st March 2006. To achieve this goal, they shall
be keen to reciprocate fast with parties who shall be fast in initiating a
response, initiating evaluation and finalizing negotiations.
Merits and business prospects of present invention on antacids:
Antacids as a major Pharma market:
is a very vibrant, fast growing market related to lifestyle diseases. This is
also a market where OTC drugs are most profitable proposition and are sought
after with preference by rule in plenty and thrive in the market. With ever
increasing professional competition in the world, a number of those who need
transitory treatment by OTC drugs is ever increasing.
Limitations of presently available antacids:
However, the drugs that are presently available are far inadequate in their
efficacy and they have several undesirable side effects. Inadequacies of present
range of drugs are fully covered by this invention.
available antacids are broadly divided into two groups.
group is composed of inorganic, acid neutralizing antacids.
group is composed of Active Pharmaceutical Ingredients (APIs) which act to
regulate metabolism to generate an effect of lowering the acidity by various
ways such as Proton-pump-inhibitors (such as Lansoprezole, Omeprezole), H2
– receptor antagonists (such as Cimetidine, Famotidine, Nizatidine,
antacids of the second group are available only on prescription and are not
meant for treatment of occasional bouts of minor to medium episodes of acidity.
Long term risks of some of them are not known, and all of them are exposed to
risks of unknown drug interactions if other drugs are being taken at the same
time. Further, many people tend to avoid metabolic drugs if simpler and equally
effective alternative is available.
of inorganic antacids are well known. Undesirable side effects arising from
inorganic antacids have been described elaborately in literature.
systemic antacid, such as sodium bicarbonate can cause alkalosis and
the antacids are derived from aluminium, calcium and magnesium, which are not
so readily soluble. They form relatively insoluble compounds in the digestive
tract, however, they are also absorbed systemically leading to toxicity. This
absorption may enhance significantly in case of patients having ulcerative
Ingestion of large amount of calcium can result in a milk-alkali syndrome
which involves hypercalcemia, alkalosis and renal failure.
Magnesium containing antacids in the long run can cause hyper magnesemia and
Aluminium containing antacids in prolonged use can cause phosphate depletion,
osteoporosis and osteomalacia as well as neurotoxicity.
toxicities of aluminium-, calcium- and magnesium-containing antacids are
common and more pertinent in patients with renal failure.
proprietary compositions of inorganic antacids aim at using different forms and
various combinations of them with a hope to counterbalance the benefits and
disadvantages from each of them. However, satisfactory compositions are yet to
be found out.
Antacids of this invention:
This invention pertains to biochemicals that are part of natural food, and their
derivatives. They are extracted from their natural sources in order to make
their antacid properties explicitly available and to be able to apply them in
therapeutically controlled manner.
part of it is that they are as effective as inorganic antacids or even better
in manner and scope of acid neutralization. They may even qualify to be sold
in OTC category as soon as some developmental and a short clinical testing
phase is over.
Antacids of this invention can be mainly divided in two categories, the first
one includes those which are known forms of nutrients considered as safe as
well as essential in normal diet. The second category is a chemical derivative
of these known forms, which may be considered as new unknown forms of
chemical forms of the first category are the ones, which are useful to control
mild and medium episodes of acidity. Being known and natural constituents of
food, no toxicity concerns come in picture; what needs to be tested in
clinical trials is only their therapeutic efficacy to determine
therapeutically effective dose. These are the forms, which obviously, may
qualify for OTC category as soon as cleared for antacid use after
demonstrating their therapeutically effective antacid capability. These forms
can be commercialized in a very short time. It may be significant here to
point it out that the number of patients who need transitory, temporary,
intermittent and for an ailment of mild to medium intensity, which is
treatable by this class of antacids of our invention, is by far the biggest
number of total antacids cases.
may be raised about their “derivatives” which have very high acid
neutralization capacity. They may be needed in advanced acidity cases, such as
in case of open ulcers. In such cases, for some period, a strong and rapid
onset acid neutralization effect is required to ensure that stomach acids are
neutralized rapidly and pH is maintained above 5. This ensures that pepsinogen
is not converted to pepsin that attacks open wounds. These are not natural
forms existing in nature as nutrients. However, the chemistry is such that as
soon as they come into contact with acids in stomach, their activity
immediately neutralizes the acids and they themselves decompose and revert
back to natural beneficial nutrient forms. The products of this neutralization
reaction does not leave behind any chemical entity which is not natural.
Clinical trials may be required for this form only to drive away any fears of
unanticipated toxicity of the derivative forms, which otherwise are least
likely to be toxic themselves, most likely to be metabolically inactive or
inert even if they remain for a long time in the derivative form after
ingestion. Incidentally, number of patients who have come to such an acute
stage is smaller in number. This component of business is relatively small.
summery, in whatever form, the antacids of this invention have practically no
possibility of serious side effects that are unmanageable in a long run and have
potential to offer very safe OTC antacids which can also be used in long term
obvious that invention with these merits is naturally positioned to rapidly
become global and win lion’s share in existing global antacids market.
Interested parties are welcome to contact at